Advanced Heart Failure Nursing Guide

📊 HF Classification by Ejection Fraction

Type	LVEF	Pathophysiology	Common Causes
HFrEF Reduced EF	<40%	Systolic dysfunction — impaired LV contractility, dilated LV, reduced stroke volume	Ischaemic heart disease, dilated cardiomyopathy, valvular disease (MR, AR)
HFmrEF Mildly Reduced EF	40–49%	Intermediate phenotype; mixed systolic/diastolic features; may improve or deteriorate	Emerging evidence — often post-MI recovery or early cardiomyopathy
HFpEF Preserved EF	≥50%	Diastolic dysfunction — impaired LV relaxation and filling, elevated filling pressures	Hypertension, obesity, type 2 diabetes, atrial fibrillation (very prevalent in GCC)

HFrEF <40%

HFmrEF 40–49%

HFpEF ≥50%

🏥 HFpEF — Nursing-Specific Considerations

⚠️

Key nursing concept: HFpEF has NO proven mortality benefit from RAAS blockade (ACEi/ARB/MRA) in most trials. Management is symptom-focused. SGLT2i (dapagliflozin, empagliflozin) are the first agents with proven benefit in HFpEF.

HFpEF Nursing Priorities

Diuresis for fluid congestion (symptom relief — no survival benefit alone)
Aggressive BP control — target systolic <130 mmHg
Rhythm control for AF — AF worsens filling; rate OR rhythm control
Weight management — obesity is a major driver; every kg matters
Diabetes management — HbA1c targets with SGLT2i preferred
Exercise tolerance monitoring — submaximal exercise recommended

AF Management in HFpEF

AF is both a cause and consequence of HFpEF
Rate control: bisoprolol, digoxin (limited use), or diltiazem if no systolic dysfunction
Rhythm control: consider cardioversion or ablation — improves haemodynamics
Anticoagulation: DOACs (rivaroxaban, apixaban) preferred over warfarin
Monitor for tachycardia-mediated cardiomyopathy — can worsen EF
Nurse role: monitor HR at rest and with activity, report sustained tachycardia >100 bpm

🏃 NYHA Functional Classification

Symptom-based — can change with treatment. Document at every encounter.

Class	Description	Nursing Implications
I	No symptoms with ordinary activity	Prevention focus; medication adherence education; annual echo
II	Slight limitation — symptoms with moderate exertion (stairs, walking uphill)	Daily weights; low-sodium diet education; monitor exercise tolerance
III	Marked limitation — symptoms with minimal exertion (dressing, slow walking)	Frequent monitoring; fluid restriction likely; consider referral to HF specialist
IV	Symptoms at rest; unable to perform any activity without discomfort	Admission likely; consider advanced therapies or palliative pathway; frequent APN review

🅰️ ACC/AHA Stages A–D

Stage is permanent — does not improve. Guides prevention and escalation decisions.

Stage	Description	Nursing Focus
A	At risk — no structural disease, no symptoms (diabetic, hypertensive)	Primary prevention; risk factor modification; lifestyle coaching
B	Pre-HF — structural disease present, no symptoms (reduced EF, prior MI)	Initiate GDMT; cardioprotective medications; patient education
C	Symptomatic HF — current or prior symptoms with structural disease	Optimise therapy; self-management support; HF nurse follow-up
D	Advanced/refractory HF — repeated hospitalisations despite optimal therapy	Goals of care; advanced therapies (LVAD, transplant) or palliative transition

💊 The "Fantastic Four" — HFrEF Evidence-Based Medications

✅

Four pillars of HFrEF therapy — each independently reduces mortality. Aim to initiate and uptitrate all four in eligible patients (NYHA II–III, stable). Together they reduce mortality by ~60% vs placebo.

Drug Class	Example Agents	Mechanism	Key Nursing Monitoring
ACEi / ARB	Ramipril, Perindopril / Candesartan, Valsartan	RAAS blockade — reduces afterload and preload, prevents myocardial remodelling	BP (hypotension), renal function (creatinine), potassium, cough (ACEi)
ARNi (Sacubitril/Valsartan)	Entresto (Sacubitril-Valsartan)	Combined neprilysin inhibition + ARB; enhances natriuretic peptides + RAAS blockade	Hypotension (more than ACEi alone), angioedema risk — must NOT be combined with ACEi; 36h washout from ACEi required; monitor BNP levels (will be elevated by mechanism)
Beta-Blocker	Bisoprolol, Carvedilol, Metoprolol succinate	Blocks sympathetic activation; reduces HR, BP, arrhythmia risk, reverse remodelling	HR (target 55–70 bpm), BP, fatigue, cold extremities, bronchospasm (avoid in severe asthma)
MRA	Spironolactone, Eplerenone	Mineralocorticoid receptor antagonist — reduces aldosterone effect, reduces fibrosis	Potassium (hyperkalaemia risk — especially with ACEi/ARB), renal function, gynaecomastia (spironolactone)
SGLT2 inhibitor	Dapagliflozin (Farxiga), Empagliflozin (Jardiance)	Glucosuria, osmotic diuresis, metabolic effects; reduces HF hospitalisations and mortality	Genital mycotic infections, DKA risk (especially T1DM), hold perioperatively, monitor renal function

⚠️

ARNI (Sacubitril-Valsartan) Critical Alert: NEVER combine with ACEi — risk of life-threatening angioedema. Must wait ≥36 hours after stopping ACEi before starting ARNI. Monitor closely for hypotension — combination is more potent than ACEi alone.

Mnemonic: The "Fantastic Four" for HFrEF

ACEi/ARB/ARNI — RAAS blockade; start ARNI if tolerating ACEi for ≥36h washout

Beta-blocker — Bisoprolol, Carvedilol, Metoprolol succinate ONLY (not atenolol)

MRA — Spironolactone or Eplerenone; watch potassium

SGLT2i — Dapagliflozin or Empagliflozin; benefit even in non-diabetics

⚡ Precipitating Factors for ADHF

Identifying and reversing the precipitant is as important as treating the decompensation itself. Always ask: "What triggered this admission?"

Most Common in GCC

Dietary sodium excess — the #1 precipitant in GCC; restaurant food, traditional cuisine, processed foods; Ramadan dietary changes
Medication non-compliance — cost, side effects, polypharmacy, language barriers, fasting and omitting morning medications
Infection — pneumonia, UTI, sepsis (increased metabolic demand)
Atrial fibrillation (new onset) — rapid ventricular response worsens filling

Other Important Triggers

Acute coronary syndrome (ACS) — new MI precipitates acute decompensation
Anaemia — reduces oxygen delivery; high prevalence of iron deficiency in GCC HF patients
Hypertensive crisis — sudden afterload increase
Pulmonary embolism
Fluid overload from IV fluids or renal failure progression
Medication changes (e.g., starting NSAIDs, steroids, calcium channel blockers)
Thyroid disease (hypo/hyperthyroid)

🩺 ADHF Clinical Profiles (Wet/Dry × Warm/Cold)

Haemodynamic profiling guides initial management. Assess perfusion (warm vs cold) and congestion (wet vs dry) independently.

Profile	Congestion	Perfusion	Clinical Signs	Initial Management
Wet-Warm	Yes (elevated filling pressures)	Adequate (warm peripheries)	Dyspnoea, oedema, elevated JVP, bibasal crackles, BP normal or elevated, warm dry skin	IV diuresis (furosemide), vasodilators (GTN if SBP >110), fluid restriction, upright position, oxygen
Wet-Cold	Yes	Impaired (low output)	All of above PLUS: cold clammy extremities, oliguria, altered consciousness, SBP <90, narrow pulse pressure, mottling	Inotropes (dobutamine), vasopressors if distributive shock, cautious diuresis, IABP consideration, senior/ICU review urgently
Dry-Warm	No	Adequate	Compensated; may have fatigue/mild dyspnoea; no oedema; euvolaemic; normal JVP	Optimise GDMT; do NOT diurese further (will worsen renal function); outpatient management
Dry-Cold	No	Impaired	Low output without congestion; end-stage picture; fatigue, poor UO, low BP, no oedema	Cautious fluid challenge to assess preload responsiveness; inotropic support; advanced HF team review

ℹ️

Most common ADHF presentation: Wet-Warm (~70% of admissions). This is the "classic" decompensated HF — fluid overloaded but maintaining adequate perfusion. Treat aggressively with IV diuresis.

🚨 ADHF Initial Treatment Bundle

Immediate Nursing Actions (First Hour)

Position upright — sitting, legs dependent (reduces preload, improves ventilation)
Oxygen: target SpO2 94–98% (avoid hyperoxia — vasoconstrictive); high-flow if SpO2 <88%
IV access — large-bore; send bloods (FBC, U&E, BNP, troponin, LFT, TFT, glucose)
12-lead ECG — rule out ACS/arrhythmia as precipitant
Continuous monitoring: SpO2, ECG, non-invasive BP, RR
Urinary catheter insertion — hourly urine output monitoring
IV furosemide: if no prior diuretics — 40 mg IV; if on oral furosemide — double the oral dose IV
CXR — assess pulmonary oedema, cardiomegaly, pleural effusion
Strict fluid balance chart — input/output documentation
Weigh patient on admission (baseline for fluid removal tracking)

Urine Output Targets & Diuresis Monitoring

Target urine output: >100 ml/hr during active IV diuresis
Reassess at 2 hours — if UO inadequate, double furosemide dose or add metolazone
Daily weight: aim for 0.5–1 kg weight loss per day during diuresis
Monitor serum electrolytes q8–12h — hypokalaemia and hypomagnesaemia are common
Monitor creatinine — some creatinine rise acceptable (haemoconcentration); significant rise (>50%) consider over-diuresis
Signs of adequate decongestion: resolution of crackles, JVP normalising, weight reduction, improved dyspnoea

⚠️

Daily weight is the single most sensitive indicator of fluid status. A 1 kg weight gain = approximately 1 litre of fluid retention. Document every morning before breakfast.

🫁 Respiratory Support in ADHF

Modality	Indication	Benefit	Nursing Setup
Conventional O2 (nasal cannula/mask)	SpO2 <94%; mild hypoxia	Corrects hypoxaemia	Titrate to maintain SpO2 94–98%; avoid >98% (vasoconstriction)
CPAP (Continuous Positive Airway Pressure)	SpO2 <90% despite O2; significant respiratory distress; acute pulmonary oedema	Increases FRC, reduces work of breathing, reduces preload and afterload, improves oxygenation; reduces intubation rate	Well-fitting mask; CPAP 5–10 cmH2O; monitor for claustrophobia; ensure patient can protect airway; hourly RR and SpO2; contraindicated if vomiting/aspiration risk
HFNO (High-Flow Nasal Oxygen)	Moderate respiratory failure; SpO2 <92% on standard O2; alternative to CPAP if poorly tolerated	High FiO2 delivery; modest positive pressure; humidified comfortable; reduces dead space	Flow 30–60 L/min; FiO2 titrated; heated humidifier; monitor SpO2, RR, work of breathing; watch for nasal bridge skin breakdown
BiPAP / NIV	Hypercapnic respiratory failure or CPAP failure	Reduces CO2, supports ventilation and oxygenation	Specialist setup; senior input; monitor ETCO2 if available

🧮 ADHF Clinical Profile Classifier & Diuretic Calculator

Enter clinical parameters to identify the haemodynamic profile and receive management guidance.

SpO2 (%)

Respiratory Distress

Peripheral Oedema

Extremities

Systolic BP (mmHg)

Oral Furosemide Dose (mg)

CARDIOGENIC SHOCK ALERT — Wet-Cold Profile + SBP <90 mmHg detected. Consider inotrope/vasopressor support. Senior physician and ICU review immediately. Do NOT delay.

Clinical Profile

SpO2 / Oxygenation

Recommended IV Furosemide Dose

Management Priorities

💉 Inotrope Indications

⚠️

Inotropes are NOT routine therapy for HF. They are reserved for acute low-output states (cardiogenic shock, wet-cold profile) or as bridge-to-decision in advanced HF. Chronic inotrope use increases arrhythmia risk and mortality.

Wet-cold haemodynamic profile (low perfusion + congestion)
Cardiogenic shock — MAP <65 mmHg or SBP <90 mmHg with evidence of end-organ hypoperfusion
Bridge to decision — awaiting LVAD implantation or cardiac transplantation
Post-cardiotomy low output syndrome
Palliative continuous inotropes for Stage D HF (comfort/quality of life)

🔬 Inotrope Comparison Table

Drug	Class / Mechanism	Dose Range	Key Effects	Side Effects / Nursing Alerts
Dobutamine	Synthetic catecholamine — Beta-1 agonist (primary), mild Beta-2, mild Alpha-1	2–20 mcg/kg/min IV infusion; titrate by response	Increased contractility (inotropy), modest HR increase, modest vasodilation	Tachycardia (most common — may precipitate AF/VT), hypotension at low doses, tolerance with prolonged use, may worsen ischaemia. Requires central line or dedicated IV access.
Milrinone	Phosphodiesterase III inhibitor (PDE3i) — increases cAMP	Loading dose 50 mcg/kg over 10 min (often omitted); maintenance 0.25–0.75 mcg/kg/min	Positive inotropy + vasodilation (both pulmonary and systemic); lusitropic (improves relaxation)	Hypotension (vasodilation — more prominent than dobutamine), ventricular arrhythmias, renally cleared (reduce dose in AKI). Preferred in patients on chronic beta-blockers (works independently of beta receptors).
Levosimendan	Calcium sensitiser + K-ATP channel opener; does NOT increase intracellular calcium	Loading 12 mcg/kg over 10 min (optional); maintenance 0.1–0.2 mcg/kg/min for 24h	Inotropy without increased myocardial oxygen demand; vasodilation (preload reduction); sustained haemodynamic benefit 24–48h post-infusion due to active metabolite (OR-1896)	Hypotension (most significant), headache, tachycardia. Monitor BP closely during infusion. Effect persists for up to 1 week — monitor for prolonged hypotension after infusion ends. Not available in all GCC formularies.
Noradrenaline (Norepinephrine)	Catecholamine — Alpha-1 > Beta-1 agonist; primarily vasopressor	0.01–3 mcg/kg/min; titrate to MAP target ≥65 mmHg	Potent vasoconstriction (increases SVR), modest positive inotropy, raises BP	Peripheral ischaemia/necrosis (extravasation risk — MUST use central line), reflex bradycardia, hypertension, reduced renal/mesenteric perfusion at high doses. First-line vasopressor in cardiogenic shock with vasodilation (wet-cold + low SVR).
Dopamine	Endogenous catecholamine — dose-dependent receptor activation	Low dose: 1–3 mcg/kg/min; Mid: 3–10 mcg/kg/min; High: >10 mcg/kg/min	Low: dopaminergic (renal/mesenteric vasodilation); Mid: Beta-1 inotropy; High: Alpha-1 vasoconstriction	Tachycardia and arrhythmias (more than noradrenaline), nausea. Important: "Renal-dose dopamine" for renal protection is NOT evidence-based — clinical trials show no benefit. Do not use solely for renal protection.

📡 Inotrope Monitoring — Nursing Protocol

Mandatory Monitoring During Inotrope Infusion

Continuous ECG monitoring — watch for sustained ventricular tachycardia (VT), AF with rapid ventricular response
Continuous arterial line BP monitoring preferred — non-invasive BP unreliable in shock
Hourly urine output — surrogate for renal perfusion and cardiac output adequacy
SpO2 continuous
Capillary refill time — q2h minimum
Mentation / GCS — sign of cerebral perfusion
Skin temperature — warm vs cold peripheries
Serum lactate — q4–6h in cardiogenic shock; rising lactate = deterioration
Electrolytes (K+, Mg2+) at least q6–8h — inotropes increase arrhythmia risk in hypokalaemia

Inotrope Weaning Protocol

Do NOT abruptly stop inotropes — clinical deterioration risk (sudden loss of cardiac support)
Wean over minimum 24–48 hours — reduce dose by 25–50% per step
Clinical markers of readiness to wean: UO >0.5 ml/kg/hr, warm peripheries, MAP ≥65 without escalation, improving mental status
After each dose reduction: observe for 2–4 hours before further reduction
Ensure oral GDMT is optimised or initiated before weaning
Document haemodynamic response to each dose change

Palliative Inotropes (Stage D HF)

Continuous low-dose dobutamine via PICC or tunnelled central line at home or in hospice
Goal: symptom relief (comfort), not survival — patient and family consent essential
Managed by HF specialist team with home nursing support
Regular reassessment of goals of care — patient may choose discontinuation

⚠️

Arrhythmia Alert: All positive inotropes increase myocardial excitability. Ensure serum K+ >4.0 mmol/L and Mg2+ >0.8 mmol/L before and during infusion. Continuous 5-lead ECG monitoring mandatory.

🏥 Vasopressors in Cardiogenic Shock — Clinical Decision Guide

When to use Noradrenaline vs Dobutamine vs Both ▼

Noradrenaline first when: MAP <65 despite fluid optimisation; predominantly vasodilatory shock component (warm-cold phenotype with low SVR); distributive cardiogenic shock.

Dobutamine add-on when: cardiac output remains low despite adequate MAP on noradrenaline; cold extremities, oliguria, rising lactate despite adequate BP.

Milrinone alternative when: patient is on chronic beta-blockade (dobutamine response blunted by beta-receptor downregulation); milrinone works via cAMP pathway independent of beta receptors.

Key principle: In pure cardiogenic shock (wet-cold), treat the low-output state first. Optimise cardiac output with inotropes; use vasopressors only if vasodilation is contributing.

IABP (Intra-Aortic Balloon Pump) Overview ▼

IABP is a mechanical circulatory support device inserted via femoral artery into the descending aorta. It inflates during diastole (increases coronary perfusion) and deflates during systole (reduces afterload).

Indications in HF: Cardiogenic shock post-MI, bridge to LVAD/transplant, mechanical complications of MI (acute MR, VSD).

Nursing monitoring: Timing of inflation/deflation (waveform assessment), limb perfusion checks (ipsilateral leg), anticoagulation monitoring (heparin infusion), insertion site for bleeding/haematoma, accidental displacement (avoid hip flexion >30°).

Note: IABP-SHOCK II trial showed IABP did NOT reduce 30-day mortality in cardiogenic shock post-MI. Use has declined in favour of Impella devices where available.

⚡ ICD in Heart Failure — Primary Prevention

Implantable Cardioverter-Defibrillator (ICD) reduces sudden cardiac death (SCD) risk in HF patients with severely reduced EF.

Indication	Criteria	Evidence
Primary prevention of SCD	HFrEF with LVEF ≤35%; NYHA II–III; optimal medical therapy for ≥3 months; life expectancy >1 year	MADIT-II, SCD-HeFT trials — ~30% relative risk reduction in SCD
Secondary prevention	Survived VF or haemodynamically significant VT; no reversible cause	AVID, CASH, CIDS trials

ℹ️

ICD does NOT improve cardiac output or symptoms — it prevents SCD only. Patients still require optimised GDMT for symptom management and mortality reduction.

ICD Nursing Monitoring

Device check at clinic every 6–12 months (remote telemetry preferred)
Patient education: avoid strong electromagnetic fields (MRI precautions — confirm MRI-conditional device), airport security, use of TENS machines, keep mobile phones >15 cm from device
If device fires (shock delivered): document time/circumstances; ECG strip; assess for triggering arrhythmia; if multiple shocks = "storm" — urgent cardiology review
Signs of ICD malfunction: inappropriate shocks (conscious, no haemodynamic compromise), failure to shock (VF/VT without device activation)

🔄 Cardiac Resynchronisation Therapy (CRT-P and CRT-D)

CRT Indications

HFrEF with LVEF ≤35%
NYHA II–IV despite optimal GDMT
Sinus rhythm with LBBB morphology and QRS duration ≥150 ms (strongest indication)
QRS 120–149 ms with LBBB — still indicated
CRT-P = pacemaker function only
CRT-D = combined CRT + ICD (used if ICD indication also present)

Mechanism

Biventricular pacing resynchronises LV and RV contraction — corrects electromechanical dyssynchrony caused by LBBB. Increases stroke volume and reduces functional MR. Can significantly improve LVEF over 3–6 months.

CRT Nursing Monitoring (Same principles as pacemaker — see pacemaker guide)

Ensure >98% biventricular pacing — AF or frequent ectopics reduce resynchronisation benefit
Monitor for lead dislodgement post-implant (first 24–48h): LV lead most common
AF management: AF reduces CRT benefit — rate control target HR <70 for optimal biventricular pacing percentage
6-minute walk test: use to objectively measure functional improvement over time
NYHA reassessment at 3 and 6 months post-CRT
Pocket site inspection: redness, swelling, wound breakdown
Twiddler's syndrome: patient manipulation of device causing lead rotation — avoid in anxious patients

📡 Haemodynamic Monitoring Devices

Swan-Ganz Catheter (Pulmonary Artery Catheter — PAC) ▼

Balloon-tipped catheter inserted via central vein (internal jugular or subclavian), advanced into the pulmonary artery. Allows direct measurement of right-sided and pulmonary haemodynamics.

Parameter	Normal	Significance in HF
PCWP (Pulmonary Capillary Wedge Pressure)	4–12 mmHg	>18 mmHg = pulmonary congestion; >25 mmHg = severe congestion
Cardiac Output (CO)	4–8 L/min	<4 L/min = low output state
Cardiac Index (CI)	2.5–4 L/min/m²	<2.2 = cardiogenic shock range
SVR (Systemic Vascular Resistance)	800–1200 dyn·s/cm5	Elevated in cold HF; low in distributive component
Pulmonary Artery Pressure	Systolic 15–30 mmHg	Elevated in pulmonary hypertension secondary to HF

Nursing responsibilities: Zero transducer at phlebostatic axis; document waveforms at each reading; confirm balloon deflated when not wedging; prevent air embolism; watch for PA rupture (haemoptysis — rare but life-threatening); daily insertion site care.

CardioMEMS — Implantable PA Pressure Monitor ▼

CardioMEMS is a wireless, battery-free sensor implanted in the pulmonary artery during right heart catheterisation. Patients transmit PA pressure readings from home daily via a pillow-like antenna.

Benefit: Champion trial showed 37% reduction in HF hospitalisations. Allows pre-emptive diuretic adjustment before clinical symptoms develop — pulmonary pressures rise days before weight/symptoms change.

Nurse-guided diuretic adjustment: Based on PA diastolic pressure — protocol-driven adjustments to furosemide dose guided by HF nurse, validated against physician-set parameters. Empowers nurses to manage outpatient HF proactively.

Nursing role: Educate patient on daily transmission (lying on left side, 2 minutes per reading); review transmitted data; act on pre-specified pressure thresholds; document trends; coordinate with HF physician when escalation required.

Implantable Loop Recorder (ILR) ▼

Small subcutaneous device (same size as USB stick) implanted under chest skin. Continuously records ECG for up to 3 years. Transmits data remotely via bedside transmitter.

Indications in HF: Unexplained syncope or pre-syncope; suspected paroxysmal AF; arrhythmia monitoring without ICD indication; assessment of AF burden.

Nursing: Ensure regular remote transmissions; teach patient to activate manual recording during symptomatic events; minimal wound care post-implant (small incision); MRI-conditional versions available.

🏃 Cardiac Rehabilitation in Heart Failure

Benefits of Exercise Training in HF

Improves exercise tolerance and VO2 max
Reduces NYHA functional class
Improves quality of life scores
Reduces HF hospitalisations (HF-ACTION trial)
Reverses skeletal muscle wasting (sarcopenia)
Improves autonomic balance — reduces sympathetic tone
Reduces depressive symptoms

Contraindications for Aerobic Exercise in HF

Decompensated ADHF (active pulmonary oedema)
Unstable angina or ACS within 5 days
Significant arrhythmia not controlled (sustained VT, rapid AF)
Symptomatic severe valve disease (especially aortic stenosis)
Recent cardiac surgery or device implantation (<4 weeks)
Hypertrophic obstructive cardiomyopathy (high-intensity contraindicated)
Pericarditis or myocarditis — absolute contraindication
Resting SBP >180 mmHg or DBP >110 mmHg

ℹ️

GCC Context: Cardiac rehabilitation uptake is low in GCC — cultural, language, and infrastructural barriers. Many programmes are hospital-based; home-based telerehabilitation is emerging. Nurse-led walking programmes (Borg RPE 11–13/20) are feasible and evidence-supported in stable HF.

🫀 LVAD — Overview (Advanced Device)

Left Ventricular Assist Device (LVAD) is a mechanical circulatory support pump implanted surgically, connected from the LV apex to the ascending aorta. For comprehensive LVAD nursing, refer to the dedicated LVAD Nursing Guide.

Indications

Bridge to Transplant (BTT): maintain patient alive and stable while awaiting donor heart
Destination Therapy (DT): permanent therapy in patients ineligible for transplant
Bridge to Recovery: for reversible cardiomyopathy (post-partum, myocarditis)
Bridge to Decision: short-term while evaluating options

Key LVAD Nursing Principles

LVAD patients have non-pulsatile flow — standard BP cuff may not work; use Doppler to measure mean arterial pressure
Driveline exit site care — infection is leading cause of LVAD morbidity
Anticoagulation (warfarin + aspirin) — monitor INR closely; target INR 2.0–3.0
Alarm response: understand pump alarms (low flow, power loss) — patient and caregiver training essential

🏥 Stage D Heart Failure — Definition

⚠️

Stage D HF (Refractory HF): Persistent NYHA IV symptoms despite optimal guideline-directed medical therapy. Characterised by repeated hospitalisations (≥2 per year), inability to wean from IV diuretics/inotropes, end-organ dysfunction (renal, hepatic), and profound functional limitation.

Markers of Advanced/Stage D HF

NYHA IV symptoms at rest or minimal exertion despite maximally tolerated GDMT
≥2 HF hospitalisations in 12 months
Progressively rising BNP/NT-proBNP with worsening renal function
Intolerance to ACEi/ARB/BB due to hypotension or renal failure
Dependent on IV diuretics or inotropes for symptom control
Cachexia / cardiac wasting
6-minute walk distance <300 metres
VO2 max <12 ml/kg/min on cardiopulmonary exercise testing

Advanced Therapy Options (When Applicable)

Cardiac transplantation — gold standard; limited by donor availability; complex eligibility
LVAD as destination therapy — see Device Therapy tab
Chronic inotrope infusion (palliative) — comfort-focused, not survival-prolonging
Palliative/supportive care pathway — when advanced therapies not appropriate or desired

⚠️

Not all Stage D patients are eligible for LVAD or transplant. Age, comorbidities, frailty, and patient preference guide decisions. Palliative pathway is always appropriate and should be offered.

💬 Goals of Care Conversations — Nursing Role

The transition from curative/life-prolonging intent to comfort-focused/palliative intent is one of the most important conversations in Stage D HF. Nurses play a critical role in facilitating and supporting this process.

Nursing Role in Goals of Care

Identify patients with Stage D features — flag for goals-of-care discussion
Attend family meetings; document wishes clearly in nursing notes
Elicit patient values: quality of life vs length of life priorities
Explore understanding: does the patient/family understand the prognosis? Correct misconceptions gently
Facilitate advance care planning: advance directives, resuscitation decisions
Coordinate with social work, chaplaincy, and palliative care team
Reassess goals regularly — they may change as condition evolves
Document agreed goals clearly with designation (DNR/AND orders as appropriate)

GCC Cultural Context

Family-centred decision making: In GCC culture, families are often the primary decision-makers, especially for patients who are elderly or incapacitated. Engage family early and respectfully.
Islamic perspectives: Islam permits withdrawal of burdensome/futile therapy while maintaining comfort care — this is NOT considered active euthanasia. Scholars broadly support transition to palliative care when further treatment is futile.
Use professional interpreters — never rely on family members for translation of goals-of-care discussions
Acknowledge grief and distress; chaplaincy (Islamic scholar if requested) support available in most GCC hospitals
Document all discussions clearly in English and Arabic where possible

😌 Symptom Management in Palliative HF

Symptom	Evidence-Based Management	Nursing Role
Dyspnoea	Low-dose oral morphine (2.5–5 mg q4h) — evidence-based for refractory dyspnoea in HF; reduces respiratory drive and sensation of breathlessness. Oxygen only if SpO2 <90%. Fan therapy effective. Anxiolytics (lorazepam) for air hunger with anxiety.	Regular dyspnoea assessment (modified Borg/numerical scale); ensure morphine available and prescribed; fan at bedside; upright positioning; reassure patient and family
Oedema / Fluid Overload	Continue IV or SC diuretics for comfort (reduces breathlessness, abdominal distension); goal is symptom relief, not fluid targets. Mouth care important if fluid restricted.	Skin integrity monitoring (oedematous skin fragile); limb elevation; gentle moisturising; paracentesis/thoracentesis for comfort if indicated
Fatigue	Energy conservation techniques; pacing of activities; treat reversible contributors (anaemia, hypothyroidism, depression); GDMT optimisation (within tolerance)	Activity planning; assist with ADLs without taking over independence; explore meaning and value of preserved activities
Depression and Anxiety	Prevalence ~40% in Stage D HF. SSRIs (sertraline) safe in HF. Cognitive-behavioural therapy. Anxiolytics for acute episodes. Psychological support services.	Screen using PHQ-9 or GAD-7; non-pharmacological support; presence and listening; refer to psychology/psychiatry; involve family in support
Pain	Often underrecognised in HF. Musculoskeletal pain from oedema/immobility; hepatic pain from congestion. Step-wise analgesia. NSAIDs contraindicated.	Regular pain assessment; position changes; avoid NSAIDs (worsen fluid retention and renal function); report uncontrolled pain

ℹ️

Opioids for Dyspnoea: Low-dose morphine for refractory dyspnoea in palliative HF is evidence-based and does NOT hasten death at appropriate doses. Nurses should feel confident administering and advocating for this treatment.

🔌 ICD Deactivation — Ethical & Nursing Framework

When and Why to Discuss ICD Deactivation ▼

As HF progresses to Stage D and the patient's trajectory is toward natural death, the ICD may deliver uncomfortable shocks during the dying process. ICD deactivation should be discussed proactively with all Stage D patients.

Ethical framework: Deactivating an ICD (or pacemaker if patient is pacemaker-dependent) is ethically equivalent to withdrawing any other life-sustaining treatment. It is not euthanasia. The patient has the right to refuse any treatment, including device therapy.

When to initiate discussion: At transition to palliative/comfort-focused care; when patient expresses preference not to receive shocks; at any stage D admission if goals of care not yet addressed.

Nursing Role in ICD Deactivation Process ▼

Nurses do NOT deactivate ICDs — this requires a cardiologist and device technician (using programmer)
Nursing role: initiate conversation with team when patient raises concerns about shocks; ensure patient/family wishes are documented; support patient through the discussion
After deactivation: the anti-tachycardia therapy is off — patient may die from VF/VT; this is expected and aligned with goals of care
If pacing-dependent: discuss pacemaker deactivation separately — more complex ethical consideration as patient may experience bradycardia and symptoms
In GCC: involve family; consider Islamic scholarly input if family needs guidance; document clearly

🕊️ End-of-Life Care in Heart Failure

HF Dying Trajectory

HF has a characteristically unpredictable dying trajectory — patients may have a relatively stable course punctuated by acute decompensations, with sudden death possible at any stage. This differs from cancer (steady decline). The uncertainty makes prognostication and family education challenging.

Educate family: sudden death is possible even in "stable" Stage D
Terminal phase signs: Cheyne-Stokes breathing, mottling, reduced urine output, reduced consciousness, cold peripheries extending centrally
Comfort measures: mouth care (moistened swabs), pressure area care, minimise intrusive monitoring, ensure pain and dyspnoea controlled
Discontinue non-comfort medications: statins, aspirin, ACEi — may stop; diuretics (SC if needed) and opioids continue for comfort

Family Education and Support

Explain expected events clearly — avoid medical jargon
Reassure family that comfort is maintained throughout
Advise on what to expect: changes in breathing, skin colour, reduced intake — these are normal dying signs
Explore after-death wishes: cultural/religious practices, organ donation discussions where appropriate
Bereavement support: provide information on hospital bereavement services; follow-up call to family after death
Fluid restriction at end of life: comfort-focused mouth care replaces large fluid intakes; explain rationale to family
Liverpool Care Pathway equivalent (Integrated Care Pathway for dying): used in some GCC hospitals — document care, goals, medication review

📋 Quick Reference — HF Classification Tables

NYHA Classification (Exam Format)

Class	Symptom Threshold	Pill
I	No symptoms with ordinary activity	Asymptomatic
II	Symptoms with moderate exertion (stairs, uphill)	Mild Limitation
III	Symptoms with minimal exertion (dressing)	Marked Limitation
IV	Symptoms at rest	Severe / Bed-bound

EF Categories (Exam Format)

Type	EF Cut-off	Key Fact
HFrEF	<40%	All "Fantastic Four" indicated
HFmrEF	40–49%	SGLT2i proven; consider GDMT
HFpEF	≥50%	SGLT2i only proven agent; treat comorbidities

ACC/AHA Stages (Exam Format)

Stage	Description	Key Point
A	At risk — no structural disease	Prevention; does NOT have HF yet
B	Structural disease — no symptoms (pre-HF)	Echo abnormal; start GDMT early
C	Symptomatic HF with structural disease	Majority of HF patients; optimise therapy
D	Refractory HF despite optimal therapy	Advanced therapy or palliative pathway

⚠️

Exam tip: ACC/AHA Stages only progress forward (A → B → C → D). NYHA Class can improve with treatment. A patient can be Stage C NYHA II if symptoms have improved with therapy.

💊 The "Fantastic Four" — Exam Summary

Drug Class	Examples	Key Monitoring	Special Notes
ACEi / ARB	Ramipril, Lisinopril / Candesartan	BP, K+, creatinine, dry cough (ACEi)	Stop if AKI, hyperkalaemia >5.5, angioedema. Switch to ARB if cough.
ARNI	Sacubitril/Valsartan (Entresto)	BP (hypotension more likely), angioedema signs, BNP (will rise — not decompensation marker on ARNI)	NEVER with ACEi. 36h washout. Preferred over ACEi/ARB in HFrEF.
Beta-blocker	Bisoprolol, Carvedilol, Metoprolol succinate	HR (target 55–70), BP, symptoms of fatigue/cold extremities	Start LOW, go SLOW. Never start in acute decompensation. Carvedilol also alpha-blocker (more hypotension).
MRA	Spironolactone, Eplerenone	K+, renal function (q1–2 weeks on initiation)	Contraindicated if K+ >5.0 or eGFR <30. Gynaecomastia with spironolactone → switch to eplerenone.
SGLT2i	Dapagliflozin, Empagliflozin	Genital hygiene, DKA signs, renal function	Works in diabetic AND non-diabetic HFrEF. Also now indicated for HFpEF. Hold if surgery/prolonged fasting.

🩺 Inotrope Comparison — Exam Table

Drug	Mechanism	Primary Effect	Main Side Effect	Special Indication
Dobutamine	Beta-1 agonist	Inotropy (increases CO)	Tachycardia, arrhythmias	First-line inotrope for cardiogenic shock
Milrinone	PDE3 inhibitor	Inotropy + vasodilation	Hypotension, arrhythmias	Patients on beta-blockers (works independently)
Levosimendan	Calcium sensitiser	Inotropy without ↑O2 demand	Prolonged hypotension	Sustained effect 24–48h post-infusion
Noradrenaline	Alpha-1 > Beta-1 agonist	Vasopressor (↑SVR, ↑BP)	Peripheral ischaemia, hypertension	Cardiogenic shock with vasodilation component
Dopamine	Dose-dependent (DA, Beta-1, Alpha-1)	Dose-dependent BP + inotrope	Tachyarrhythmias	"Renal dose" NOT evidence-based for renal protection

🩻 ADHF Clinical Profiles — Exam Flashcard

Profile	Congestion	Perfusion	BP Pattern	First Treatment
Wet-Warm	Yes	Normal	Normal or high	IV furosemide + GTN (if SBP >110)
Wet-Cold	Yes	Impaired	Low <90 mmHg	Inotropes + vasopressors; ICU review
Dry-Warm	No	Normal	Normal	Optimise oral GDMT; avoid diuresis
Dry-Cold	No	Impaired	Low	Cautious fluid challenge; inotropes; advanced HF team

Mnemonic: Wet-Cold = Cardiogenic Shock — think COLD SHOCK

Cold clammy extremities

Oliguria — urine output <0.5 ml/kg/hr

Lactate rising — tissue hypoperfusion

Decreasing conscious level / confusion

🎓 DHA / DOH / SCFHS / QCHP High-Yield Advanced HF Questions

Q1: A patient with HFrEF (EF 28%) is on ramipril and bisoprolol. What is the next medication to add? ▼

Answer: Spironolactone (MRA) — complete the "Fantastic Four". After ACEi + Beta-blocker, add MRA (spironolactone/eplerenone) if K+ <5.0 and eGFR >30. Then add SGLT2i. In clinical practice, all four should be initiated and uptitrated simultaneously where tolerated. ARNI should replace ACEi in eligible patients (the question may instead ask to switch ramipril to sacubitril/valsartan after 36h washout).

Q2: A patient on oral furosemide 80 mg/day is admitted with ADHF. What is the appropriate IV furosemide starting dose? ▼

Answer: 80 mg IV — the standard rule is to double the oral dose when converting to IV. Oral furosemide 80 mg = IV furosemide 80 mg (the bioavailability difference is captured by doubling). So: oral dose × 2 = IV starting dose. Target urine output >100 ml/hr. Reassess at 2 hours; if inadequate, double again or add metolazone.

Q3: Which inotrope is preferred for cardiogenic shock in a patient already on chronic carvedilol? ▼

Answer: Milrinone — Milrinone works via PDE3 inhibition (increases cAMP) independently of beta receptors. Dobutamine requires intact beta-1 receptors for its effect — chronic beta-blocker therapy causes receptor downregulation and blunts dobutamine response. Milrinone bypasses beta receptors entirely, making it the preferred inotrope when patient is on beta-blockers.

Q4: What is the primary nursing concern when starting sacubitril/valsartan (Entresto) in a patient currently on lisinopril? ▼

Answer: Risk of angioedema due to concurrent ACEi use — Sacubitril inhibits neprilysin, which normally degrades bradykinin. ACEi also increases bradykinin (blocks ACE which degrades bradykinin). Combining both leads to dangerously elevated bradykinin — life-threatening angioedema. Must wait ≥36 hours after stopping ACEi before starting ARNI. Also monitor for hypotension (ARNI more potent vasodilator than ACEi alone). Note: BNP levels will rise on ARNI (neprilysin inhibited) — this does NOT mean decompensation. Use NT-proBNP for monitoring instead, or correlate with clinical picture.

Q5: A Stage D HF patient with an ICD requests that the device be turned off. What is the nurse's role? ▼

Answer: Support, document, and facilitate — do NOT deactivate independently. ICD deactivation is the patient's legal and ethical right. The nurse's role is to: (1) Acknowledge and validate the request without judgement; (2) Inform the medical team and document the request clearly; (3) Facilitate a goals-of-care discussion with cardiology, palliative care, and family as appropriate; (4) Ensure the patient has capacity to make the decision; (5) Arrange for a cardiologist and device technician to reprogram/deactivate the ICD using a programmer. In GCC, involve family and consider Islamic scholarly input if requested. Document everything meticulously.

Q6: What is the most common precipitant for ADHF admission in GCC patients? ▼

Answer: Dietary sodium excess — GCC dietary patterns (high-salt traditional cuisine, restaurant food, processed foods, Ramadan dietary changes) make dietary sodium excess the leading precipitant for ADHF in the Gulf region. Medication non-compliance is the second most common. This underscores the importance of dietary education in all HF patients — salt restriction to <2g sodium/day (<5g salt/day) is recommended. Nurses should routinely ask about dietary changes at every admission.

Q7: A patient in cardiogenic shock (wet-cold, SBP 78 mmHg) is being started on dobutamine. What monitoring is MANDATORY? ▼

Answer: (1) Continuous invasive arterial line BP monitoring — non-invasive BP unreliable in shock; (2) Continuous cardiac monitoring (5-lead ECG) — dobutamine is arrhythmogenic; watch for VT/VF; (3) Hourly urine output via urinary catheter — surrogate for renal perfusion; (4) Serum lactate q4–6h — rising lactate = deteriorating perfusion; (5) Electrolytes (K+, Mg2+) q6–8h — hypokalaemia increases arrhythmia risk; (6) Temperature and capillary refill q2h — assess peripheral perfusion response to treatment.

Q8: What is the CRT implantation threshold for QRS duration and EF? ▼

Answer: EF ≤35%, QRS ≥150 ms with LBBB morphology, NYHA II–IV, sinus rhythm, despite optimal GDMT for ≥3 months. QRS 120–149 ms with LBBB is also an indication (Class IIa). CRT is NOT indicated in RBBB morphology (evidence weak) or narrow QRS. LBBB with QRS ≥150 ms represents the group with most robust evidence of benefit. Also consider CRT in patients with AF if ventricular rate controlled to achieve >98% biventricular pacing.

Advanced Heart Failure — GCC Nursing Guide